Liquidia Financial Results
Liquidia Corporation reported Q3 2026 financial results, highlighted by $222.7 million in YUTREPIA net product sales, a 31% increase over the prior quarter. The company recorded a net loss of $236.3 million, which was primarily driven by a $389.7 million litigation settlement charge to resolve all outstanding disputes with United Therapeutics. Liquidia ended the quarter with $396.1 million in cash and cash equivalents.
- Term
- Q3 2026
“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.”
Dr. Roger Jeffs, Liquidia’s Chief Executive Officer